(Alliance News) - GlaxoSmithKline PLC and Johnson & Johnson on Saturday reported long-term trial data showing a drug combination provides continued suppression of HIV.
Cabotegravir, developed by ViiV Healthcare, and rilpivirine, created by J&J unit Janssen, offered "continued safety and efficacy". ViiV is majority-owned by GSK, with Pfizer Inc and Shionogi Ltd also owning stakes.
"The ATLAS-2M 96-week data reinforces the therapeutic potential of this long-acting regimen for the treatment of HIV. It provides an option that could change the treatment experience for some people living with HIV by removing the need for daily pills for the treatment of HIV," Hans Jaeger, a trial investigator, said.
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)
